Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Dual IKZF2 and CK1α Degrader Targets Acute Myeloid Leukemia Cells

Sun Mi Park, David Miyamoto, Grace Han, Mandy Chan, Nicole Curnutt, Nathan Tran, Anthony Velleca, Jun Hyun Kim, Alexandra Schurer, Kathryn Chang, Christina M Woo, Michael G Kharas

Blood (2022) 140 (Supplement 1): 675–676.

https://doi.org/10.1182/blood-2022-167678

Published: 2022

Journal Articles

Outcome of Initial Observation in Mantle Cell Lymphoma

Anita Kumar, MD, Zhitao Ying, MD, Anna Alperovich, MD, Ahmet Dogan, Paul A Hamlin, Jr., MD, Craig H. Moskowitz, MD, Carol S Portlock, MD, Andrew D. Zelenetz, Zhigang Zhang, PhD, Kaitlin M Woo, MS, Anas Younes, MD

Blood (2016) 128 (22): 1803.

https://doi.org/10.1182/blood.V128.22.1803.1803

Published: 2016

Journal Articles

Outcomes of Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Salvage Chemotherapy and Intention to Transplant in the Rituximab Era

Santosha A. Vardhana, MD PhD, Craig H. Moskowitz, MD, Craig S. Sauter, MD, Matthew J Matasar, MD MS, Natasha Galasso, Kaitlin M Woo, MS, Zhigang Zhang, PhD

Blood (2015) 126 (23): 1986.

https://doi.org/10.1182/blood.V126.23.1986.1986

Published: 2015

Journal Articles

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan Kettering Cancer Center

Bartlomiej Getta, MBBS,, Kaitlin M Woo, MS, Sean Devlin, PhD, Jae H. Park, MD, Omar Abdel-Wahab, Martin S Tallman, MD

Blood (2015) 126 (23): 1476.

https://doi.org/10.1182/blood.V126.23.1476.1476

Published: 2015

Journal Articles

TARC Predicts PET-Normalization and Event Free Surival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin

Alison J Moskowitz, MD, Sun Cho, Martin Fleisher, PhD, Kaitlin M Woo, MS, Zhigang Zhang, PhD, Stephanie Fox, Susan J McCall, MSN ANP-BC, Heiko Schoder, MD, Joachim Yahalom, MD, Craig H Moskowitz, MD

Blood (2015) 126 (23): 180.

https://doi.org/10.1182/blood.V126.23.180.180

Published: 2015

Journal Articles

Interim Analysis of a Randomized Phase II Trial Comparing Continuous Lenalidomide and Dexamethasone to Autologous Stem Cell Transplantation in Multiple Myeloma Patients Responsive to Lenalidomide and Dexamethasone Induction

Jonathan I Weltz, BA, Heather Landau, MD, Nikoletta Lendvai, MDPhD, David J Chung, MDPhD, Alexander M. Lesokhin, MD, Sean M. Devlin, PhD, Elyn Riedel, MA, Kaitlin M Woo, MA, Amanda Stellman, BA, Danielle Chimento, BA, Tarun Kewalramani, MD, Ola Landgren, MD PhD, Sergio Giralt, MD, Raymond L. Comenzo, MD, Hani Hassoun, MD

Blood (2014) 124 (21): 3991.

https://doi.org/10.1182/blood.V124.21.3991.3991

Published: 2014

Journal Articles

Analysis of VDT-PACE Utilization in Multiple Myeloma Patients Treated at MSKCC for Relapsed Disease or Cytoreduction and Stem Cell Mobilization after Initial Induction Therapy

Kristen Beyer, PharmD, BCOP, Samuel Rosner, Kaitlin M Woo, MA, Sean M. Devlin, PhD, Heather Landau, MD, Hani Hassoun, MD, Nikoletta Lendvai, MD PhD, David J Chung, MD PhD, Nelly G. Adel, PharmD, BCOP, BCPS, Marcin Puto, PharmD, BCOP, Ola Landgren, MD, PhD, Sergio Giralt, MD, Alexander M. Lesokhin, MD

Blood (2014) 124 (21): 3459.

https://doi.org/10.1182/blood.V124.21.3459.3459

Published: 2014

Journal Articles

Potent Inhibition of Multiple Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients

Susan J Lee, Tina M Woo, Shirin Arastu-Kapur, PhD, Alvin F Wong, Pharm.D., Thomas E Renau, PhD, Christopher J Kirk, PhD

Blood (2011) 118 (21): 5068.

https://doi.org/10.1182/blood.V118.21.5068.5068

Published: 2011

Journal Articles

Effects of Renal Function on the Pharmacokinetics of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Sunil Sharma, MD, Emile Voest, MD, PhD, Nicole Hagner, MD, P.O. Witteveen, MD, PhD, Martijn Lolkema, MD, PhD, Neeraj Agarwal, MD, Sue-zette Valera, Jason Li, PhD, Derek Mires, Maria Grazia Porro, PhD, Margaret M. Woo, PharmD, Dagmar Hess, MD

Blood (2011) 118 (21): 5001.

https://doi.org/10.1182/blood.V118.21.5001.5001

Published: 2011

Journal Articles

Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Dagmar Hess, MD, Nicole Hagner, MD, Sally Clive, MD, Hans Gelderblom, MD, PhD, Eva Rossmann, MD, PhD, Neeraj Agarwal, MD, Maria Grazia Porro, PhD, Thomas Hengelage, PhD, Annie St-Pierre, PhD, Lucien Gazi, PhD, Jason Li, PhD, Margaret M. Woo, PharmD, Sunil Sharma, MD

Blood (2011) 118 (21): 5007.

https://doi.org/10.1182/blood.V118.21.5007.5007

Published: 2011

Journal Articles

Characteristics of Thrombocytopenia in Patients Treated with Oral Panobinostat (LBH589).

Rong Lin, MD, Jing Hu, PhD, Sofia Paul, PhD, Joanne Schindler, Margaret M. Woo, Stan Spence, PhD, Samit Hirawat, MD, Harald A. Weber, MD

Blood (2009) 114 (22): 2740.

https://doi.org/10.1182/blood.V114.22.2740.2740

Published: 2009

Journal Articles

Population Pharmacokinetics of Panobinostat (LBH589) in Patients with Advanced Solid Tumors and Hematologic Malignancies Following Intravenous and Oral Administration.

Marina Savelieva, Praz, Dr., sc., math., Margaret M. Woo, Harald A. Weber, MD, Samit Hirawat, MD, Sofia Paul, PhD, Joanne Schindler, Roland Fisch, PhD

Blood (2009) 114 (22): 3780.

https://doi.org/10.1182/blood.V114.22.3780.3780

Published: 2009

Journal Articles

QT Interval Measurements in Patients with Hematologic Malignancies and Solid Tumors Treated with Oral Panobinostat (LBH589).

Harald A. Weber, MD, Feng Tai, PhD, Sofia Paul, PhD, Joanne Schindler, Margaret M. Woo, Stan Spence, PhD, Jennifer Marlowe, Rong Lin, MD

Blood (2009) 114 (22): 3781.

https://doi.org/10.1182/blood.V114.22.3781.3781

Published: 2009

Journal Articles

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity.

Susan D. Demo, PhD, Monette A. Aujay, BS, Eileen Goldstein, BS, Guy J. Laidig, PhD, Francesco Parlati, PhD, Yan Lu, PhD, Kevin D. Shenk, BS, Congcong M. Sun, MS, Catherine Sylvain, PhD, Tina M. Woo, BS, Hanjie Zhou, PhD, Mark K. Bennett, PhD

Blood (2006) 108 (11): 4398.

https://doi.org/10.1182/blood.V108.11.4398.4398

Published: 2006

Journal Articles

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders.

Francesco Parlati, PhD, Monette A. Aujay, B.S., Susan D. Demo, Ph.D., Eileen D. Goldstein, B.S., Jing Jiang, B.S., Christopher J. Kirk, Ph.D., Guy J. Laidig, Ph.D., Yan Lu, M.S., Tony Muchamuel, M.S., Kevin D. Shenk, M.S., Catherine Sylvain, Ph.D., Congcong M. Sun, M.S., Tina M. Woo, B.S., Han-Jie Zhou, Ph.D., Mark K. Bennett, Ph.D.

Blood (2006) 108 (11): 4392.

https://doi.org/10.1182/blood.V108.11.4392.4392

Published: 2006

Journal Articles

Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome.

Christopher J. Kirk, PhD, Monette A. Aujay, B.S., Mark Ho, B.S., Jing Jiang, B.S., Guy J. Laidig, Ph.D., Evan R. Lewis, Ph.D., Yan Lu, M.S., Tony Muchamuel, M.S., Tina M. Woo, B.S., Congcong M. Sun, M.S., Catherine Sylvain, Ph.D., Jinfu Yang, Ph.D., Han-jie Zhou, Ph.D., Mark K. Bennett, Ph.D.

Blood (2006) 108 (11): 3581.

https://doi.org/10.1182/blood.V108.11.3581.3581

Published: 2006

Journal Articles

Multicenter Phase I Studies To Evaluate the Safety, Tolerability, and Clinical Response to Intensive Dosing with the Proteasome Inhibitor PR-171 in Patients with Relapsed or Refractory Hematological Malignancies.

Owen A. O’Connor, PhD, MD, Robert Z. Orlowski, MD, PhD, Melissa Alsina, MD, Keith Stewart, MBChB, Suzanne Trudel, MD, Marcy K. Vallone, Tina M. Woo, Pedro R. Urquilla, MD, Christopher J. Molineaux, PhD, Andre Goy, MD

Blood (2006) 108 (11): 2430.

https://doi.org/10.1182/blood.V108.11.2430.2430

Published: 2006

Journal Articles

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.

Christopher J. Kirk, PhD, Mark K. Bennett, PhD, Tonia J. Buchholz, MS, Susan D. Demo, PhD, Mark N. Ho, BS, Jing Jiang, BS, Guy J. Laidig, PhD, Evan R. Lewis, PhD, Kevin D. Shenk, BS, Mark S. Smyth, PhD, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina M. Woo, BS, Christopher J. Molineaux, PhD

Blood (2005) 106 (11): 609.

https://doi.org/10.1182/blood.V106.11.609.609

Published: 2005

Journal Articles

Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation

D Przepiorka, C Ippoliti, I Khouri, M Woo, R Mehra, D Le Bherz, S Giralt, J Gajewski, H Fischer, H Fritsche, AB Deisseroth, K Cleary, R Champlin, K Besien, B Andersson, R Maher, W Fitzsimmons

Blood (1996) 88 (11): 4383–4389.

https://doi.org/10.1182/blood.V88.11.4383.4383

Published: 1996

NARROW

Dual IKZF2 and CK1α Degrader Targets Acute Myeloid Leukemia Cells

Outcome of Initial Observation in Mantle Cell Lymphoma

Outcomes of Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Salvage Chemotherapy and Intention to Transplant in the Rituximab Era

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan Kettering Cancer Center

TARC Predicts PET-Normalization and Event Free Surival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin

Interim Analysis of a Randomized Phase II Trial Comparing Continuous Lenalidomide and Dexamethasone to Autologous Stem Cell Transplantation in Multiple Myeloma Patients Responsive to Lenalidomide and Dexamethasone Induction

Analysis of VDT-PACE Utilization in Multiple Myeloma Patients Treated at MSKCC for Relapsed Disease or Cytoreduction and Stem Cell Mobilization after Initial Induction Therapy

Potent Inhibition of Multiple Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients

Effects of Renal Function on the Pharmacokinetics of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Characteristics of Thrombocytopenia in Patients Treated with Oral Panobinostat (LBH589).

Population Pharmacokinetics of Panobinostat (LBH589) in Patients with Advanced Solid Tumors and Hematologic Malignancies Following Intravenous and Oral Administration.

QT Interval Measurements in Patients with Hematologic Malignancies and Solid Tumors Treated with Oral Panobinostat (LBH589).

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity.

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders.

Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome.

Multicenter Phase I Studies To Evaluate the Safety, Tolerability, and Clinical Response to Intensive Dosing with the Proteasome Inhibitor PR-171 in Patients with Relapsed or Refractory Hematological Malignancies.

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.

Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only